The past couple of years may have looked different for the NACDS Annual Meeting, but that doesn’t mean participating companies haven’t been busy. Nonetheless, many attendees are anxious to gather again in person and showcase the innovations their companies have been developing. Here are some of the participating companies and the exciting new products and services that attendees can expect to see at the trade association’s annual event, taking place April 23 to 26 at The Breakers in Palm Beach, Fla.
Bedminster, N.J.-based Alembic is introducing lacosamide tablets in dosage strengths of 50 mg, 100 mg, 150 mg and 200 mg.
The medication is the generic of UCB’s Vimpat tablets. It is indicated for the treatment of partial-onset seizures in patients aged one month old and older.
Alembic’s lacosamide tablets come in 60-count bottles.
This marks Alembic USA’s 92nd product launch since commencement of U.S. operations in October 2015.